8-K: Xeris Biopharma Reports Strong Q3 2026 Results, Raises Guidance
Quarterly Results
Xeris Biopharma announced robust third quarter 2026 financial results, with total revenue up 44% year-over-year, driven by strong Recorlev performance, leading to raised full-year and 2030 revenue outlooks.
Summary
- Total revenue for the third quarter of 2026 reached $107.2 million, a 44% increase year-over-year.
- Recorlev net revenue surged by 93% to $71.5 million.
- Full-year 2026 total revenue guidance has been raised to $395 million $405 million.
- The 2030 total revenue outlook has been increased to over $1 billion, up from a previous estimate of approximately $750 million.
- Net income for Q3 2026 was $11.3 million, a significant improvement from $0.6 million in Q3 2025.
- Adjusted EBITDA for Q3 2026 was $30.8 million, up from $17.4 million in the prior year period.
- The company retired its 2028 Convertible Senior Notes on July 15, 2026, eliminating $34 million in debt and $3 million in annual interest expense.
- The pivotal Phase 3 study for XP-8121 (Cornerstone) is on track to initiate by year-end 2026, with topline data expected in late 2028 and potential launch in 2030.
Sentiment
Score: 8
Explanation: StockSavvy.ai views this as a highly positive report, driven by significant revenue growth, raised guidance, and strong product performance, particularly from Recorlev.
Positives
- Total revenue increased by 44% year-over-year to $107.2 million in Q3 2026.
- Recorlev net revenue experienced substantial growth of 93% year-over-year, reaching $71.5 million.
- Full-year 2026 total revenue guidance was raised to $395 million $405 million.
- The 2030 total revenue outlook was significantly increased to over $1 billion.
- Gross margin improved to 88% in Q3 2026 from 85% in Q3 2025.
- Net income for Q3 2026 was $11.3 million, a substantial increase from $0.6 million in the prior year.
- Adjusted EBITDA improved significantly to $30.8 million in Q3 2026 from $17.4 million in Q3 2025.
- The company successfully retired its 2028 Convertible Senior Notes, reducing debt and interest expense.
Negatives
- Gvoke revenue decreased by 14% year-over-year to $21.7 million, offset by a one-time $4 million gross-to-net adjustment.
- Research and development expenses increased by 48% in Q3 2026 compared to Q3 2025, primarily for XP-8121.
- Selling, general and administrative expenses increased by 38% in Q3 2026 compared to Q3 2025, due to commercial expansion.
- Net loss for the nine months ended September 30, 2026, was $17.6 million, compared to a net loss of $10.5 million in the same period last year, due to a one-time charge related to convertible notes exchange agreements.
Risks
- The company's financial position and need for financing to fund product development programs or commercialization efforts.
- Whether its products will achieve and maintain market acceptance in a competitive business environment.
- Reliance on third-party suppliers, including single-source suppliers.
- Reliance on third parties to conduct clinical trials.
- The ability of its product candidates to compete successfully with existing and new drugs.
- The ability to protect its intellectual property and proprietary technology.
- Accuracy and completeness of assumptions and the ability to accurately estimate future financial results and market opportunities.
- General macroeconomic and geopolitical conditions, including the possibility of an economic downturn, political unrest, trade disputes, changes in U.S. governmental priorities and resources, announced or implemented tariffs or export controls and market volatility.
Future Outlook
Full-year 2026 total revenue guidance has been raised to $395 million to $405 million. The company also raised its 2030 total revenue outlook to over $1 billion, up from approximately $750 million. XP-8121 Phase 3 initiation is expected by year-end 2026, with topline data in late 2028 and potential launch in 2030.
Management Comments
- "This new trajectory reflects growth from the full enterprise. Net product revenue in the third quarter grew more than 43% year-over-year, led by Recorlev, where our expanded commercial team moved from build to yield and delivered record referrals and new patient starts."
- "We now see Recorlev on a path to nearly $1 billion in annual net revenue three to four years sooner than previously expected."
- "Given the strong momentum across Recorlev, Gvoke, and Keveyis, we are raising our full-year total revenue guidance to $395$405 million."
Industry Context
StockSavvy.ai notes that Xeris Biopharma's strong performance aligns with a trend of increasing demand for specialized biopharmaceutical treatments in endocrine and rare diseases. The company's focus on innovative medicines and its successful commercialization of key products like Recorlev position it well within this growing market segment.
Comparison to Industry Standards
- The 44% year-over-year revenue growth in Q3 2026 significantly outpaces the average growth rates seen in many established pharmaceutical companies, which often operate in the mid-to-high single digits.
- Recorlev's 93% year-over-year net revenue increase is exceptional and suggests strong market penetration and competitive advantage, potentially exceeding the typical growth trajectory of new drug launches in competitive therapeutic areas.
- The improved gross margin of 88% is robust and indicates efficient manufacturing and supply chain management, often a benchmark for profitability in the biopharmaceutical sector.
- The raised 2030 revenue outlook to over $1 billion signifies aggressive but potentially achievable long-term growth targets, comparable to successful specialty pharma companies that have scaled significantly.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Independent Director | N/A | Menassie M. Taddese | 2026-11-02 | Appointment to the Board of Directors. |
Stakeholder Impact
- Shareholders: Positive impact due to increased revenue guidance, improved profitability, and a strengthened long-term outlook, potentially leading to increased shareholder value.
- Employees: Potential for increased opportunities and job security due to company growth and expansion, particularly in commercial operations.
- Creditors: Positive impact due to improved financial performance and debt reduction (retirement of convertible notes), strengthening the company's creditworthiness.
Next Steps
- Initiate the pivotal Phase 3 Cornerstone study for XP-8121 by year-end 2026.
- Present real-world evidence analysis at the American Thyroid Association 95th Annual Meeting (November 4-7, 2026).
- Participate in 1x1 meetings and a fireside chat at the Jefferies London Healthcare Conference (November 16-19, 2026).
- Participate in 1x1 meetings and a fireside chat at the Piper Sandler Healthcare Conference (December 1, 2026).
Key Dates
| Date | Description |
|---|---|
| 2026-07-15 | Completion of retirement of 8.00% Convertible Senior Notes due 2028. |
| 2026-09-09 | Program overview detailing the clinical development program for XP-8121. |
| 2026-10-06 | USPTO granted U.S. Patent No. 12,751,937 for XP-8121. |
| 2026-10-13 | USPTO issued U.S. Patent No. 12,758,502 covering Keveyis. |
| 2026-11-02 | Menassie M. Taddese appointed to the Xeris Biopharma Board of Directors. |
| 2026-11-04 | Start of American Thyroid Association 95th Annual Meeting. |
| 2026-11-05 | Announcement of third quarter 2026 financial results and business highlights. |
| 2026-12-01 | Piper Sandler Healthcare Conference participation. |
Recommendation
strong buyThe filing demonstrates exceptionally strong financial performance with significant year-over-year revenue growth, particularly from key products like Recorlev. The upward revision of both near-term and long-term revenue guidance, coupled with improved profitability metrics (net income and Adjusted EBITDA), indicates robust operational execution and a positive market reception for the company's products. The successful retirement of debt and progress in pipeline development (XP-8121) further solidify the company's growth trajectory and reduce financial risk, warranting a strong buy recommendation.
Keywords
Xeris Biopharma, Recorlev, Gvoke, Keveyis, XP-8121, hypothyroidism, Cushings syndrome, severe hypoglycemia
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.